Project Grant R01HL172022
Award Date 8/9/24
Completion Date 5/31/29
Dollars Obligated $1.3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Danville, PA 17822, USA
Similar Awards
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $784,203 to Pennsylvania State University, doing business as Penn State Milton S. Hershey Medical Center, to develop and test a small, durable, hemocompatible centrifugal blood pump for use in children with heart failure awaiting transplant. The goal is to create a pediatric ventricular assist device (VAD) that can support children weighing 10-35 kg for up to 1...
- This Project Grant award of $320,838 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding the development of a "Fail Safe, High Output Failing Fontan Pump" by Perfusion Solutions Inc. (PSI). The project aims to design a long-term cavopulmonary assist system that can provide the necessary blood flows and pressures for patients with single ventricle heart disease who have undergone the Fontan surgical...
- The National Heart, Lung, and Blood Institute (NHLBI), under the federal Cardiovascular Diseases Research program (CFDA 93.837), awarded a $306,643 project grant to Mira Medical, LLC to develop a new extracorporeal membrane oxygenation (ECMO) pump designed to efficiently accommodate the low flow rates needed for pediatric and neonatal patients. The project aims to design, develop, and test a low-flow ECMO pump capable of operating at flow rates from 0.05 to 0.5 L/min, which is an order of...
- This National Science Foundation (NSF) Project Grant award under CFDA 47.041 (Engineering) supports the development of a new computational model to predict the complex interactions between ventricular assist devices (VADs) and the beating native heart. The goal is to create a "digital twin" of an experimental mock circulatory loop used for testing VAD safety and efficacy. This $195,291 award, effective August 1, 2024 through July 31, 2026, will result in a lumped parameter model that...
- This Project Grant award of $769,994, awarded on September 5, 2025 by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), supports research to investigate the impact of left ventricular assist device (LVAD) implantation on cerebral hemodynamics and cognition. The project aims to clarify the relationship between LVAD physiology and neurovascular health, with the goal of identifying hemodynamic metrics that can be used to personalize and improve...
- Percassist Inc. received a $663,129 Project Grant award from the National Heart Lung and Blood Institute of the Department of Health and Human Services. The award was made under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research. The grant funds the development of a percutaneous ventricular assist device for chronic heart failure patients. Specifically, Percassist will design and test a balloon catheter implant that can be delivered minimally...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,024,635 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Corvion, Inc. in Webster, Texas to develop a Totally Implanted Left Ventricular Assist Device (TI-LVAD). The goal is to create an ultra-low-power blood pump, implantable battery, and wireless charging system that eliminates the need for a percutaneous driveline and external power supply, reducing complications and improving quality of life...
- This Project Grant award of $870,467.00, provided by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), supports the development of Ension Inc.'s Bearingless Flux Reversal Motor for Neonatal and Pediatric Extracorporeal Life Support Applications. The project aims to address shortcomings of the current clinically available bearingless pediatric blood pump, the Abbott PediMag, by creating an innovative, multifunctional, and advanced compact ECLS...
- This Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of unfixed, immune-compatible, and regenerative xenogeneic biomaterials for transcatheter heart valve replacements by Vivita Technologies, Inc. (Davis, CA). The $496,255 award aims to validate Vivita's patented SPEAR Platform™ technology, which produces "BARE™ patches" that avoid rapid immune destruction...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $455,826 to conduct a double-blind, randomized, placebo-controlled trial to determine the effects of chronic sildenafil administration on vascular remodeling during left ventricular assist device (LVAD) support. The study aims to assess the impact of sildenafil, a phosphodiesterase-5 inhibitor, on aortic stiffness, carotid...